Joined HECOBASE in 2022

An Intelligent Energy Storage Integrator

Founded in July 2022, Spoweress is an energy storage system integrator dedicated to advancing intelligent and efficient solutions for the global energy industry.

Leveraging its self-developed core technologies — including the Battery Management System (BMS), Power Conversion System (PCS), and Energy Management System (EMS) — Spoweress delivers optimized integration where each component works in harmony to achieve a synergistic “1 + 1 > 2” effect.

By combining innovation, engineering excellence, and smart control systems, Spoweress empowers power plants, renewable energy operators, and industrial users to enhance efficiency, stability, and sustainability across the energy value chain.

Joined HECOBASE in 2023

A leading innovator in advanced cryogenic and hydrogen technologies.

Fullcryo was founded in 2016 in Beijing, and is a high-tech enterprise specializing in large-scale cryogenic equipment below 20K. 

Originating from decades of R&D at the Technical Institute of Physics and Chemistry, CAS, and backed by national scientific equipment programs, Fullcryo integrates leading research, advanced manufacturing, and industrial capital. 

The company develops helium extraction technologies to reduce China’s import dependence and provides hydrogen liquefaction and storage solutions that lower costs and promote large-scale hydrogen use - aiming to become a global leader in cryogenic and gas system technologies.

Joined HECOBASE in 2022

First-in-class immuno-oncology therapeutics

Founded in December 2020, BioTroy Therapeutics is dedicated to developing first-in-class immuno-oncology therapies.

The company’s founder, Dr. Xu, discovered two novel immune-oncology targets—unreported previously—and revealed their critical roles in tumor immune evasion.These breakthroughs open new avenues for developing targeted therapies for patients who do not respond to or develop resistance against anti–PD-1 treatment.

Joined HECOBASE in 2023

A leading company advancing AI-driven immunology and infectious disease therapies.

Established in 2015, Drug Farm develops innovative treatments for infectious and immunological diseases through its proprietary platforms.

Its IDInVivo⁺ system enables genetic screening in living animals with intact immune systems, while the MedChem5 platform leverages deep learning to accelerate first-in-class drug discovery.

Together, these technologies have led to the identification of novel immunity targets and the development of first-in-class drug candidates now in clinical stages.

Joined HECOBASE in 2023

A leading innovator in ion channel–based drug discovery.

Founded in February 2016, Leadopharma focuses on developing innovative therapies for refractory diseases associated with ion channels.

Leveraging its proprietary high-throughput ion channel screening platform, the company pioneers a unique approach of modifying the structural backbone of existing drugs to design novel molecules with independent intellectual property rights.

Leadopharma currently has three very promising first-in-class small molecule drug candidates in early clinical development, advancing new possibilities in the treatment of complex ion channel–related disorders.

Joined HECOBASE in 2024

A gene therapy company pioneering first-in-class treatments for telomere-associated diseases

Founded in April 2021, Juvensis Therapeutics is a gene therapy company pioneering first-in-class treatments targeting telomere-associated mechanisms.

Its lead program aims to disrupt the vicious cycle of telomere damage, mitochondrial dysfunction, and cell apoptosis—addressing critical unmet needs in heart failure and other degenerative diseases.

Joined HECOBASE in 2022

Next-generation cloud-native AI infrastructure software provider

Baihai Technology, founded in 2021, is dedicated to making AI faster, more efficient, and cost-effective. With a core team from Tsinghua University, Baidu, and MiningLamp, averaging over 15 years of experience, Baihai builds the next-generation AI platform IDP, enabling seamless development, training, and deployment. 

Its IDP LM platform accelerates enterprise large-model applications with controllable, high-performance solutions. 

Backed by strong IP, patents, and top-tier research, Baihai is redefining how AI is built and deployed at scale.